Abdominal pain on Wegovy, Zepbound, Ozempic and other GLP-1 medicines
The short answer
Ozempic stomach pain and abdominal pain on other GLP-1 medicines need prompt medical attention if the pain is persistent or severe, sometimes radiating to the back, because the labels describe that as a sign of acute pancreatitis. All eight labels list abdominal pain in their tables: 20% of adults on Wegovy 2.4 mg against 10% on placebo, and 9% to 10% on Zepbound against 5%.
Key takeaways
- Persistent or severe abdominal pain, with or without vomiting, needs prompt medical attention. Don't wait to see if it settles.
- The labels describe that pain, sometimes radiating to the back, as a sign of acute pancreatitis.
- If you believe it's an emergency, call 911.
- Each label also warns of acute gallbladder disease, meaning gallstones and gallbladder inflammation.
- For milder discomfort, tell your prescriber, sooner if it follows a dose increase and doesn't ease.
How often it was reported in the label's trials
| Reaction | Placebon=958 | 5 mgn=630 | 10 mgn=948 | 15 mgn=941 |
|---|---|---|---|---|
| Abdominal Pain | 5% | 9% | 9% | 10% |
| Reaction | Placebon=235 | 5 mgn=237 | 10 mgn=240 | 15 mgn=241 |
|---|---|---|---|---|
| Abdominal Pain | 4% | 6% | 5% | 5% |
| Reaction | Placebon=1261 | Wegovy injection 2.4 mg once weeklyn=2116 |
|---|---|---|
| Abdominal Pain | 10% | 20% |
| Reaction | Placebon=303 | Wegovy injection 2.4 mg once weeklyn=304 | Wegovy injection 7.2 mg once weeklyn=1311 |
|---|---|---|---|
| Abdominal pain | 7% | 9% | 12% |
| Reaction | Placebon=67 | Wegovy injection 2.4 mg once weeklyn=133 |
|---|---|---|
| Abdominal Pain | 6% | 15% |
| Reaction | Placebon=262 | Ozempic 0.5 mgn=260 | Ozempic 1 mgn=261 |
|---|---|---|---|
| Abdominal pain | 4.6% | 7.3% | 5.7% |
| Reaction | Placebon=1576 | 5.5 mgn=1051 | 9 mgn=1055 | 17.2 mgn=1049 |
|---|---|---|---|---|
| Abdominal pain | 7% | 13% | 14% | 14% |
| Reaction | Placebon=362 | Semaglutide tablets 7 mgn=356 | Semaglutide tablets 14 mgn=356 |
|---|---|---|---|
| Abdominal Pain | 4% | 10% | 11% |
| Reaction | Placebon=1941 | Saxendan=3384 |
|---|---|---|
| Abdominal Pain | 3.1% | 5.4% |
| Reaction | Placebon=568 | 0.75 mgn=836 | 1.5 mgn=834 |
|---|---|---|---|
| Abdominal Pain | 4.9% | 6.5% | 9.4% |
Each medicine's figures come from its own trials, which differ in dose, length and who took part. They are not a head-to-head comparison.
If you have stomach pain on a GLP-1 medicine, the first question is how bad it is. Persistent or severe abdominal pain, with or without vomiting, needs prompt medical attention. Don’t wait to see whether it settles, and don’t decide about your next dose alone. If you believe it’s an emergency, call 911.
Abdominal pain is in every GLP-1 label’s table of common reactions. It’s also the symptom the labels use to describe two serious conditions. This page covers both sides: the routine figures and the warnings.
How often do the labels report abdominal pain?
Each figure is the share of trial patients who reported it, next to the placebo group from the same trials. A placebo group gets an inactive treatment instead of the medicine.
- Wegovy 2.4 mg injection (adults, three weight reduction trials): 20%, with 10% on placebo. The label notes this is a grouped term covering several kinds of abdominal pain. In the 7.2 mg trials: 12% on 7.2 mg, 9% on 2.4 mg and 7% on placebo.
- Foundayo (adults with obesity or overweight, two pooled trials): 13% at 5.5 mg, 14% at 9 mg and 14% at 17.2 mg, with 7% on placebo.
- Rybelsus (adults with type 2 diabetes, two trials; the label also covers Ozempic tablets): 10% at 7 mg and 11% at 14 mg, with 4% on placebo.
- Zepbound (adults with obesity or overweight, two pooled trials): 9% at 5 mg, 9% at 10 mg and 10% at 15 mg, with 5% on placebo.
- Trulicity (adults with type 2 diabetes, pooled trials): 6.5% at 0.75 mg and 9.4% at 1.5 mg, with 4.9% on placebo.
- Ozempic injection (adults with type 2 diabetes, two trials): 7.3% at 0.5 mg and 5.7% at 1 mg, with 4.6% on placebo.
- Mounjaro (adults with type 2 diabetes, two pooled trials): 6% at 5 mg, 5% at 10 mg and 5% at 15 mg, with 4% on placebo. In its cardiovascular outcomes trial, the label reports abdominal pain in 10% of patients on Mounjaro.
- Saxenda (adults, five trials): the table has two rows. Abdominal pain: 5.4%, with 3.1% on placebo. Upper abdominal pain: 5.1%, with 2.7% on placebo.
In younger patients, the Wegovy label reports 15% on 2.4 mg and 6% on placebo in adolescents with obesity. The Mounjaro label reports 22% at 5 mg and 15% at 10 mg, with 9% on placebo, in its 30-week trial in patients aged 10 and older with type 2 diabetes. Saxenda’s adolescent table lists “abdominal discomfort” at 4.8%, with 0.8% on placebo.
The labels count this reaction differently. Wegovy groups several terms into one row, and Saxenda splits them into two. That alone means you can’t compare the rows between medicines, even before you consider how the trials differ.
The timing sentences in the labels name nausea, vomiting and diarrhea. Only Wegovy’s covers gastrointestinal (stomach and bowel) reactions as a group, saying they were most frequently reported during dosage escalation, the weeks when the dose is being raised.
The pancreatitis warning
All eight labels carry a warning on acute pancreatitis, an inflammation of the pancreas. The Wegovy, Ozempic and Saxenda labels use nearly the same sentence: observe patients carefully for signs and symptoms, “which may include persistent or severe abdominal pain (sometimes radiating to the back), and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue” the medicine “and initiate appropriate management.”
The Zepbound, Mounjaro and Trulicity labels state that acute pancreatitis, “including fatal and non-fatal hemorrhagic or necrotizing pancreatitis,” has been observed in patients treated with GLP-1 receptor agonists or the medicine itself. Hemorrhagic and necrotizing pancreatitis are severe forms that involve bleeding or tissue death.
Confirmed cases in the trials were few. Zepbound’s pooled trials: 0.2% on Zepbound and 0.2% on placebo. Saxenda’s adult trials: 9 of 3,291 patients on Saxenda (0.3%) and 2 of 1,843 on placebo (0.1%). Wegovy’s adult weight reduction trials: 4 patients on Wegovy and 1 on placebo.
The gallbladder warning
Each label also warns of acute gallbladder disease, meaning gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis). Here’s what the trials reported:
- Saxenda, adults: gallstones in 2.2% on Saxenda and 0.8% on placebo; cholecystitis in 0.8% and 0.4%. The label says most Saxenda patients with these events required gallbladder removal.
- Wegovy, adults: gallstones in 1.6% on the injection and 0.7% on placebo; cholecystitis in 0.6% and 0.2%. In the adolescent trial, gallstones appear in the table at 4% on Wegovy and 0% on placebo.
- Zepbound: gallstones in 1.1% and 1% on placebo; cholecystitis in 0.7% and 0.2%.
- Foundayo: gallstones in 1% and 0.7% on placebo.
When to get help
Persistent or severe abdominal pain, with or without vomiting, needs prompt medical attention. The labels leave the decision to stop the medicine to the clinician who suspects pancreatitis. So don’t wait to see whether it settles, and don’t decide about your next dose alone. If you believe it’s an emergency, call 911.
For milder discomfort, tell your prescriber at your next contact, and sooner if it follows a dose increase and doesn’t ease. See also dyspepsia, nausea, vomiting, constipation and the side effects overview.
Frequently asked questions
Is stomach pain a side effect of Ozempic?
Yes, abdominal pain is in the Ozempic injection label's table. In two placebo-controlled trials in adults with type 2 diabetes, 7.3% of patients on 0.5 mg and 5.7% on 1 mg reported it, compared with 4.6% on placebo. The same label warns that persistent or severe abdominal pain can be a sign of acute pancreatitis, so get that kind of pain checked promptly.
How do I know if abdominal pain is pancreatitis?
You can't tell from a web page, and the labels don't ask patients to. They describe the signs prescribers watch for: persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting. Pain like that needs prompt medical attention so a clinician can assess it.
How common is pancreatitis on GLP-1 medicines?
Uncommon in the trials. In Zepbound's pooled weight reduction trials, 0.2% of patients on Zepbound and 0.2% on placebo had acute pancreatitis confirmed by adjudication, a formal review of each case. In Saxenda's adult trials it was confirmed in 0.3% of patients on Saxenda and 0.1% on placebo. The labels also describe fatal and non-fatal cases reported with GLP-1 receptor agonists.
Can a GLP-1 cause gallbladder problems?
Every label we track carries a warning on acute gallbladder disease. In Saxenda's adult trials, gallstones were reported by 2.2% of patients on Saxenda and 0.8% on placebo. In Wegovy's adult weight reduction trials, the figures were 1.6% on the injection and 0.7% on placebo. Zepbound's pooled trials reported gallstones in 1.1% of treated patients and 1% on placebo.
Sources (8)
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
Related pages
- GLP-1 side effects: what the FDA labels report
- Ozempic nausea, Zepbound nausea and the other GLP-1 labels
- Vomiting on Wegovy, Zepbound, Ozempic and other GLP-1 medicines
- Dyspepsia and indigestion on Zepbound, Wegovy, Mounjaro and other GLP-1 medicines
- Ozempic constipation and constipation on other GLP-1 medicines
- Ozempic diarrhea: what the GLP-1 labels report
